Multimodal and three-dimensional imaging of prostate cancer.

Accurate characterization of prostate cancer is crucial for treatment planning and patient management. Non-invasive SPECT imaging using a radiolabeled monoclonal antibody, 111In-labeled capromab pendetide, offers advantage over existing means for prostate cancer diagnosis and staging. However, there are difficulties associated with the interpretation of these SPECT images. In this study, we developed a 3D surface-volume hybrid rendering method that utilizes multi-modality image data to facilitate diagnosis of prostate cancer. SPECT and CT or MRI (or both) images were aligned either manually or automatically. 3D hybrid rendering was implemented to blend prostate tumor distribution from SPECT in pelvis with anatomic structures from CT/MRI. Feature extraction technique was also implemented within the hybrid rendering for tumor uptake enhancement. Autoradiographic imaging and histological evaluation were performed to correlate with the in-vivo SPECT images. Warping registration of histological sections was carried out to compensate the deformation of histology slices during fixation to help the alignment between histology and in-vivo images. Overall, the rendered volumetric evaluation of prostate cancer has the potential to greatly increase the confidence in the reading of radiolabeled monoclonal antibody scans, especially in patients where there is a high suspicion of prostate tumor metastasis.

[1]  Guido Gerig,et al.  Three-dimensional multi-scale line filter for segmentation and visualization of curvilinear structures in medical images , 1998, Medical Image Anal..

[2]  J. Schnitzer Vascular targeting as a strategy for cancer therapy. , 1998, The New England journal of medicine.

[3]  Fred L. Bookstein,et al.  Principal Warps: Thin-Plate Splines and the Decomposition of Deformations , 1989, IEEE Trans. Pattern Anal. Mach. Intell..

[4]  S. Cherry,et al.  Combining anatomy and function: the path to true image fusion , 2001, European Radiology.

[5]  A. Belldegrun,et al.  Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. , 1999, The Journal of urology.

[6]  C A Pelizzari,et al.  Using vascular structure for CT-SPECT registration in the pelvis. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  M. Ercan,et al.  Radiopharmaceuticals for the visualization of infectious and inflammatory lesions. , 2000, Current pharmaceutical design.

[8]  J. McNeal,et al.  Patterns of spread of adenocarcinoma in the prostate as related to cancer volume , 2001, The Prostate.

[9]  A. Boynton,et al.  Monoclonal antibody 7E11.C5 staining of viable LNCaP cells , 1997, The Prostate.

[10]  H. Dvorak,et al.  Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. , 1991, Cancer cells.

[11]  S. Vallabhajosula,et al.  Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  Taylor Murray,et al.  Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.

[13]  D. Bostwick,et al.  Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen , 1998, Cancer.

[14]  J. Papadimitriou,et al.  Progressive increase of apoptosis in prostatic intraepithelial neoplasia and carcinoma: comparison between in situ end-labeling of fragmented DNA and detection by routine hematoxylin-eosin staining. , 1997, Archives of pathology & laboratory medicine.

[15]  David L Wilson,et al.  Automatic registration of MR and SPECT images for treatment planning in prostate cancer. , 2003, Academic radiology.

[16]  Zhenghong Lee,et al.  PET imaging-based evaluation of aerosol drugs and their delivery devices: nasal and pulmonary studies , 2002, IEEE Transactions on Medical Imaging.

[17]  C. Cordon-Cardo,et al.  Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  Marc Levoy,et al.  Display of surfaces from volume data , 1988, IEEE Computer Graphics and Applications.

[19]  Carl-Fredrik Westin,et al.  Tissue Classification Based on 3D Local Intensity Structures for Volume Rendering , 2000, IEEE Trans. Vis. Comput. Graph..

[20]  George L. Wright,et al.  Detection and characterization of the prostate‐specific membrane antigen (PSMA) in tissue extracts and body fluids , 1995, International journal of cancer.

[21]  G. Bakale,et al.  Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers. , 2000, Urology.

[22]  S. Rosenthal,et al.  Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen. Positron emission tomography and biopsy correlation. , 1996, Clinical nuclear medicine.